Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTP001 in healthy adults and pulmonary arterial hypertension
2024-513613-12-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 2, randomised, double-blind trial of LTP001 in pulmonary arterial hypertension (PAH) (4 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability, Change in pulmonary vascular resistance and 1 more. Planned start Sep 2025; status: authorised.
02
Drugs
LTP001
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2024-513613-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513613-12-00.